Go Pro

Omega Healthcare Investors (OHI) Financials

Omega Healthcare Investors logo
$50.37 -1.00 (-1.95%)
Closing price 07/30/2026 03:59 PM Eastern
Extended Trading
$50.45 +0.08 (+0.17%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Omega Healthcare Investors

Annual Income Statements for Omega Healthcare Investors

This table shows Omega Healthcare Investors' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
225 750 100 282 341 159 417 427 242 406 590
Consolidated Net Income / (Loss)
233 767 105 294 352 164 428 439 249 418 609
Net Income / (Loss) Continuing Operations
233 767 105 294 352 164 428 439 249 418 609
Total Pre-Tax Income
235 769 106 297 344 162 416 436 256 421 624
Total Revenue
744 1,729 963 705 776 688 828 1,005 794 843 975
Net Interest Income / (Expense)
0.00 -173 -9.52 -201 -209 -223 -98 -109 -116 -65 -40
Total Interest Income
0.00 0.17 0.00 0.00 0.00 0.00 136 124 120 157 175
Loans and Leases Interest Income
- - - - - - 136 124 120 157 175
Total Interest Expense
0.00 173 9.52 201 209 223 235 233 236 222 215
Long-Term Debt Interest Expense
- 164 - 201 209 223 235 233 236 222 215
Total Non-Interest Income
744 1,902 973 906 985 911 926 1,114 910 907 1,015
Other Service Charges
78 189 101 113 124 138 1.14 3.09 3.46 6.27 13
Other Non-Interest Income
666 1,612 808 769 805 754 925 751 826 888 1,002
Provision for Credit Losses
- 9.85 - 6.69 0.00 38 78 69 45 -15 2.34
Total Non-Interest Expense
332 774 647 402 433 474 304 498 513 443 403
Other Operating Expenses
46 104 48 64 73 69 77 85 97 103 119
Depreciation Expense
211 534 288 281 302 330 342 332 320 305 325
Impairment Charge
18 117 297 57 53 72 45 38 92 24 23
Restructuring Charge
58 19 - 0.38 5.12 2.02 1.81 42 5.34 12 4.22
Other Special Charges
- - 15 - - - -162 - - - -67
Nonoperating Income / (Expense), net
-177 -176 -210 0.35 0.81 -14 -31 -2.39 20 5.08 55
Income Tax Expense
1.21 2.81 3.25 3.01 2.84 4.93 3.84 4.56 6.26 11 15
Other Gains / (Losses), net
- 0.88 2.24 0.38 11 6.14 16 7.26 -0.58 7.92 -0.22
Net Income / (Loss) Attributable to Noncontrolling Interest
8.79 17 4.49 12 11 4.22 12 12 6.62 11 19
Basic Earnings per Share
$1.30 $3.82 $0.51 $1.41 $1.60 $0.70 $1.76 $1.81 $1.01 $1.57 $1.96
Weighted Average Basic Shares Outstanding
172.24M 593.14M 197.74M 209.71M 226.81M 231.78M 239.11M 234.27M 245.30M 281.84M 295.57M
Diluted Earnings per Share
$1.29 $3.80 $0.51 $1.40 $1.58 $0.70 $1.75 $1.80 $1.00 $1.55 $1.94
Weighted Average Diluted Shares Outstanding
180.51M 403.27M 206.79M 209.71M 226.81M 231.78M 239.11M 234.27M 245.30M 281.84M 295.57M
Weighted Average Basic & Diluted Shares Outstanding
172.70M 201.64M 206.79M 209.71M 226.81M 231.78M 239.11M 234.27M 245.30M 281.84M 295.57M
Cash Dividends to Common per Share
$2.18 $2.36 $2.54 $2.64 $2.65 $2.68 $2.68 $2.68 $2.68 $2.68 $2.68

Quarterly Income Statements for Omega Healthcare Investors

This table shows Omega Healthcare Investors' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders
55 67 114 112 113 109 137 180 165 151 363
Consolidated Net Income / (Loss)
57 69 117 115 116 112 140 185 172 159 380
Net Income / (Loss) Continuing Operations
57 69 117 115 116 112 140 185 172 159 380
Total Pre-Tax Income
62 72 119 111 119 115 147 191 171 160 380
Total Revenue
179 184 212 221 219 235 252 282 229 276 527
Net Interest Income / (Expense)
-28 -22 -16 -15 -12 -9.16 -9.90 -13 -7.56 -4.60 -1.36
Total Interest Income
32 36 38 40 43 43 43 45 44 45 47
Loans and Leases Interest Income
32 36 38 40 43 43 43 45 44 45 47
Total Interest Expense
59 58 54 55 55 52 53 58 52 50 48
Long-Term Debt Interest Expense
59 58 54 55 55 52 53 58 52 50 48
Total Non-Interest Income
207 206 228 236 231 244 262 295 237 281 528
Other Service Charges
-0.83 0.54 0.39 4.60 -4.54 1.49 0.31 2.24 8.98 0.53 1.02
Net Realized & Unrealized Capital Gains on Investments
- -1.39 13 -0.24 - 10 23 28 - 3.02 247
Other Non-Interest Income
208 207 214 231 235 232 239 265 266 277 280
Provision for Credit Losses
33 8.47 -14 -9.06 -0.72 5.09 -4.77 -3.91 5.92 -3.29 -5.02
Total Non-Interest Expense
96 108 110 118 106 118 124 111 73 121 145
Other Operating Expenses
22 25 26 25 26 35 23 27 29 30 42
Depreciation Expense
76 75 74 77 79 80 81 82 83 84 82
Impairment Charge
3.95 5.29 8.18 8.62 1.74 1.24 14 1.14 6.02 0.39 0.00
Restructuring Charge
4.16 2.60 1.78 6.44 0.80 1.46 2.01 0.59 0.15 1.11 4.66
Other Special Charges
-9.71 - - - - 0.00 3.77 - - 5.43 16
Nonoperating Income / (Expense), net
12 3.99 3.15 -1.18 4.39 3.05 14 17 21 1.08 -7.22
Income Tax Expense
4.16 2.58 1.98 3.32 2.98 3.61 4.53 4.48 2.13 5.11 4.62
Other Gains / (Losses), net
-1.14 0.10 0.14 6.88 0.80 1.08 -2.19 -1.91 2.80 3.76 4.53
Net Income / (Loss) Attributable to Noncontrolling Interest
1.52 1.99 3.22 3.15 3.12 3.03 3.88 5.24 7.14 7.53 17
Basic Earnings per Share
$0.24 $0.27 $0.46 $0.43 $0.41 $0.34 $0.46 $0.60 $0.56 $0.47 $1.21
Weighted Average Basic Shares Outstanding
245.30M 247.10M 257.84M 269.95M 281.84M 289.40M 295M 295.53M 295.57M 297.80M 303.01M
Diluted Earnings per Share
$0.23 $0.27 $0.45 $0.42 $0.41 $0.33 $0.46 $0.59 $0.56 $0.47 $1.19
Weighted Average Diluted Shares Outstanding
245.30M 247.10M 257.84M 269.95M 281.84M 289.40M 295M 295.53M 295.57M 297.80M 303.01M
Weighted Average Basic & Diluted Shares Outstanding
245.30M 247.10M 257.84M 269.95M 281.84M 289.40M 295M 295.53M 295.57M 297.80M 303.01M

Annual Cash Flow Statements for Omega Healthcare Investors

This table details how cash moves in and out of Omega Healthcare Investors' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-14 87 -10 -85 22 134 -143 276 144 104 -494
Net Cash From Operating Activities
-17 625 578 499 554 708 722 626 618 749 879
Net Cash From Continuing Operating Activities
449 625 578 499 554 708 723 626 618 749 879
Net Income / (Loss) Continuing Operations
0.00 383 105 294 352 164 428 439 249 418 609
Consolidated Net Income / (Loss)
- 383 105 294 352 164 428 439 249 418 609
Provision For Loan Losses
7.87 9.85 15 0.00 11 185 117 193 45 -15 2.34
Depreciation Expense
211 267 288 281 302 330 342 332 320 305 325
Amortization Expense
22 -2.53 7.80 -1.75 3.66 -2.58 34 7.68 14 12 0.97
Non-Cash Adjustments to Reconcile Net Income
209 -32 227 -7.73 -37 35 -105 -303 47 40 -6.26
Changes in Operating Assets and Liabilities, net
0.15 -1.03 -64 -66 -77 -1.87 -93 -44 -57 -10 -53
Net Cash From Investing Activities
-397 -1,114 -285 -173 -379 -89 -524 443 -0.77 -671 -540
Net Cash From Continuing Investing Activities
-397 -1,114 -285 -173 -379 -89 -524 443 -0.77 -671 -540
Purchase of Property, Leasehold Improvements and Equipment
-191 -109 -124 -169 -53 -106 -45 -47 -38 -38 -81
Purchase of Investment Securities
-380 -1,332 -566 -556 -603 -344 -867 -602 -684 -871 -974
Divestitures
85 1.32 15 5.47 9.08 6.29 18 3.33 8.81 1.02 13
Sale and/or Maturity of Investments
89 326 391 547 459 357 476 1,105 750 303 529
Other Investing Activities, net
- - - - -132 - -89 -16 -38 -66 -27
Net Cash From Financing Activities
-65 576 -304 -411 -154 -486 -341 -789 -473 26 -838
Net Cash From Continuing Financing Activities
-65 576 -304 -411 -154 -486 -341 -789 -473 26 -836
Issuance of Debt
3,664 2,352 3,034 1,291 2,002 1,852 2,275 597 507 658 1,312
Issuance of Common Equity
590 260 59 122 516 152 274 8.11 336 1,236 607
Repayment of Debt
-3,923 -1,537 -2,869 -1,270 -2,086 -1,856 -2,227 -590 -739 -1,152 -1,924
Payment of Dividends
-370 -453 -503 -529 -585 -612 -663 -653 -670 -715 -824
Other Financing Activities, Net
-27 -45 -25 -25 0.00 -21 -0.08 -9.62 92 -0.14 -6.25
Other Net Changes in Cash
-0.22 0.08 - - 0.87 - 0.01 -2.90 0.43 -0.58 5.33

Quarterly Cash Flow Statements for Omega Healthcare Investors

This table details how cash moves in and out of Omega Healthcare Investors' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents
-113 -82 -324 321 188 -145 369 2.42 -720 -1.24 131
Net Cash From Operating Activities
165 151 184 185 229 182 239 227 231 216 218
Net Cash From Continuing Operating Activities
165 151 184 185 229 182 239 227 231 216 218
Net Income / (Loss) Continuing Operations
57 69 117 115 116 112 140 185 172 159 380
Consolidated Net Income / (Loss)
57 69 117 115 116 112 140 185 172 159 380
Provision For Loan Losses
33 8.47 -14 -7.93 2.32 5.09 23 -31 5.92 -3.29 -5.02
Depreciation Expense
76 75 74 77 79 80 81 82 83 84 82
Amortization Expense
3.65 4.96 3.04 0.78 2.21 1.38 1.02 1.06 -2.49 3.40 3.40
Non-Cash Adjustments to Reconcile Net Income
-2.48 13 2.19 9.66 13 15 -13 1.79 -9.29 4.31 -211
Changes in Operating Assets and Liabilities, net
-1.30 -19 1.73 -9.78 16 -31 7.88 -12 -18 -32 -31
Net Cash From Investing Activities
111 -47 -209 -133 -282 19 -464 -84 -12 -270 552
Net Cash From Continuing Investing Activities
111 -47 -209 -133 -282 19 -464 -84 -12 -270 552
Purchase of Property, Leasehold Improvements and Equipment
-59 -21 -35 -25 -25 -35 2.31 -21 -27 -13 -14
Purchase of Investment Securities
-218 -53 -252 -182 -377 -100 -566 -175 -133 -333 -131
Divestitures
5.79 0.94 0.31 1.59 -1.82 1.16 0.31 8.50 2.94 3.40 3.29
Sale and/or Maturity of Investments
360 26 77 72 122 184 99 101 145 73 696
Net Cash From Financing Activities
-390 -186 -299 268 243 -348 589 -139 -940 54 -639
Net Cash From Continuing Financing Activities
-390 -186 -299 268 243 -348 589 -139 -938 54 -639
Issuance of Debt
- - - 179 - 0.00 - - 641 719 408
Issuance of Common Equity
8.66 32 243 526 434 261 257 89 -0.04 105 61
Repayment of Debt
-228 -43 -849 -258 -2.63 -401 -133 -20 -1,370 -536 -827
Payment of Dividends
-170 -175 -172 -180 -188 -208 -202 -206 -209 -220 -211
Other Financing Activities, Net
- - 0.55 - -0.68 0.00 - -2.09 -0.48 -13 -71
Other Net Changes in Cash
- - - - - 1.82 3.84 -1.45 1.11 -1.05 0.25

Annual Balance Sheets for Omega Healthcare Investors

This table presents Omega Healthcare Investors' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
7,990 8,949 8,773 17,182 9,796 9,497 9,638 9,405 9,117 9,898 10,049
Cash and Due from Banks
5.42 94 86 21 24 164 21 297 443 518 27
Restricted Cash
15 - 11 2.74 9.26 4.02 3.88 3.54 1.92 30 28
Trading Account Securities
- 49 37 62 200 201 195 179 188 89 414
Loans and Leases, Net of Allowance
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net
5,725 6,326 6,279 -3,125 7,199 6,705 6,847 6,537 5,903 6,339 6,703
Goodwill
646 643 645 1,288 644 652 651 643 644 644 645
Other Assets
920 1,198 1,045 1,392 946 887 1,921 1,745 1,938 2,278 2,233
Total Liabilities & Shareholders' Equity
7,990 8,949 8,773 17,182 9,796 9,497 9,638 9,405 9,117 9,898 10,049
Total Liabilities
3,889 4,737 4,885 4,667 5,460 5,461 5,530 5,602 5,355 5,167 4,609
Short-Term Debt
230 190 290 313 125 101 0.00 19 20 0.00 242
Long-Term Debt
3,310 4,177 4,282 4,327 5,011 5,068 5,254 5,268 5,047 4,839 4,014
Other Long-Term Liabilities
15 370 18 27 323 292 277 315 288 328 353
Total Equity & Noncontrolling Interests
4,101 4,212 3,888 3,764 4,337 4,037 4,108 3,803 3,762 4,731 5,440
Total Preferred & Common Equity
3,738 3,859 3,555 3,444 4,135 3,842 3,907 3,609 3,575 4,537 5,181
Preferred Stock
- - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
3,738 3,859 3,555 3,444 4,135 3,842 3,907 3,609 3,575 4,537 5,181
Common Stock
4,628 4,881 4,956 5,095 6,015 6,176 6,451 6,338 6,696 7,944 8,723
Retained Earnings
-882 -968 -1,371 -1,609 -1,840 -2,321 -2,542 -2,749 -3,150 -3,430 -3,620
Accumulated Other Comprehensive Income / (Loss)
-8.71 -54 -30 -42 -40 -13 -2.20 20 29 23 79
Noncontrolling Interest
363 353 333 320 201 195 201 194 188 194 259

Quarterly Balance Sheets for Omega Healthcare Investors

This table presents Omega Healthcare Investors' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets
9,290 9,404 9,425 9,012 8,849 9,572 9,706 10,546 10,596 10,235 10,015
Cash and Due from Banks
245 351 555 362 35 342 368 734 737 26 39
Restricted Cash
3.34 5.82 3.21 1.25 3.94 18 36 38 38 27 145
Trading Account Securities
181 192 188 186 185 93 89 85 150 508 501
Loans and Leases, Net of Allowance
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net
6,438 6,489 6,193 5,834 5,877 6,292 6,333 6,795 6,742 6,470 6,468
Goodwill
644 644 643 644 644 645 644 645 645 644 644
Other Assets
1,779 1,723 1,844 1,985 2,103 2,183 2,236 2,248 2,284 2,559 2,217
Total Liabilities & Shareholders' Equity
9,290 9,404 9,425 9,012 8,849 9,572 9,706 10,546 10,596 10,235 10,015
Total Liabilities
5,605 5,591 5,568 5,311 4,948 5,172 4,774 5,357 5,352 4,780 4,372
Short-Term Debt
20 20 20 20 70 0.00 0.00 0.00 - 425 6.00
Long-Term Debt
5,268 5,267 5,272 5,008 4,590 4,858 4,446 5,000 4,995 4,016 4,019
Other Long-Term Liabilities
317 305 277 283 287 313 327 357 357 338 348
Total Equity & Noncontrolling Interests
3,686 3,813 3,857 3,701 3,901 4,400 4,932 5,189 5,244 5,455 5,642
Total Preferred & Common Equity
3,497 3,624 3,669 3,514 3,711 4,208 4,741 4,988 5,036 5,191 5,391
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
3,497 3,624 3,669 3,514 3,711 4,208 4,741 4,988 5,036 5,191 5,391
Common Stock
6,346 6,550 6,682 6,730 6,977 7,507 8,208 8,460 8,546 8,805 8,837
Retained Earnings
-2,870 -2,968 -3,041 -3,248 -3,300 -3,362 -3,510 -3,568 -3,587 -3,668 -3,505
Accumulated Other Comprehensive Income / (Loss)
22 41 28 32 34 63 43 97 77 54 58
Noncontrolling Interest
189 188 188 187 190 192 191 201 208 264 252

Annual Metrics And Ratios for Omega Healthcare Investors

This table displays calculated financial ratios and metrics derived from Omega Healthcare Investors' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Profitability Metrics
- - - - - - - - - - -
Valuation Ratios
- - - - - - - - - - -
Leverage & Solvency
- - - - - - - - - - -
Liquidity Ratios
- - - - - - - - - - -
Cash Flow Metrics
- - - - - - - - - - -
Efficiency Ratios
- - - - - - - - - - -
Capital & Investment Metrics
- - - - - - - - - - -
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.30 $1.91 $0.51 $1.41 $1.60 $0.70 $1.76 $1.81 $1.01 $1.57 $1.96
Adjusted Weighted Average Basic Shares Outstanding
172.24M 191.78M 197.74M 618.32M 213.40M 231.78M 239.11M 234.27M 245.30M 281.84M 295.57M
Adjusted Diluted Earnings per Share
$1.29 $1.90 $0.51 $1.40 $1.58 $0.70 $1.75 $1.80 $1.00 $1.55 $1.94
Adjusted Weighted Average Diluted Shares Outstanding
180.51M 201.64M 206.79M 419.42M 222.13M 231.78M 239.11M 234.27M 245.30M 281.84M 295.57M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $1.60 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
188.13M 196.74M 198.59M 209.71M 226.81M 231.78M 239.11M 234.27M 245.30M 281.84M 295.57M
Debt Service Ratios
- - - - - - - - - - -
Payout Ratios
- - - - - - - - - - -

Quarterly Metrics And Ratios for Omega Healthcare Investors

This table displays calculated financial ratios and metrics derived from Omega Healthcare Investors' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding
- - - - - - - - - 295,570,000.00 297,802,000.00
DEI Adjusted Shares Outstanding
- - - - - - - - - 295,570,000.00 297,802,000.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - 0.54 1.27
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-39.61% 19.48% 3.29% 20.65% 22.46% 27.43% 8.46% 27.43% - 17.75% 108.58%
EBITDA Growth
-3.57% 37.86% 31.59% 9.66% 50.69% 30.84% 11.05% 34.34% - 27.79% 119.67%
EBIT Growth
1.57% 128.42% 86.49% 22.84% 127.91% 64.43% 15.27% 55.09% - 42.40% 189.99%
NOPAT Growth
-3.20% 112.31% 88.32% 21.38% 138.22% 65.19% 13.61% 56.10% - 42.34% 195.56%
Net Income Growth
21.02% 88.21% 90.31% 22.37% 106.05% 61.60% 19.99% 60.95% - 41.51% 170.27%
EPS Growth
15.00% 80.00% 80.00% 13.51% 78.26% 22.22% 2.22% 40.48% - 42.42% 158.70%
Operating Cash Flow Growth
7.35% 36.02% 8.06% 8.11% 38.79% 20.12% 29.96% 22.62% - 18.44% -9.00%
Free Cash Flow Firm Growth
-3.96% -61.45% 205.10% -100.59% -304.61% -274.57% -329.85% -112,641.83% - 32.73% 160.36%
Invested Capital Growth
-2.87% -2.73% -5.92% 1.20% 8.38% 7.44% 19.02% 10.59% - 5.52% -5.13%
Revenue Q/Q Growth
-2.40% -4.22% 4.21% 11.23% -0.93% 7.09% -2.12% 22.71% - 20.55% 90.66%
EBITDA Q/Q Growth
-25.50% 1.56% 26.92% -1.29% 2.38% -1.17% 11.50% 19.88% - 7.06% 91.66%
EBIT Q/Q Growth
-45.28% 3.81% 58.34% -2.80% 1.53% -2.37% 19.63% 30.78% - 5.99% 143.62%
NOPAT Q/Q Growth
-48.02% 7.30% 61.51% -4.09% 2.02% -3.01% 19.72% 31.77% - 3.89% 148.60%
Net Income Q/Q Growth
-39.81% 22.69% 68.83% -1.85% 1.35% -3.78% 25.36% 31.66% - -7.79% 139.42%
EPS Q/Q Growth
-37.84% 17.39% 66.67% -6.67% -2.38% -19.51% 39.39% 28.26% - -16.07% 153.19%
Operating Cash Flow Q/Q Growth
-3.53% -8.19% 21.54% 0.42% 23.84% -20.53% 31.50% -5.25% - -6.56% 1.03%
Free Cash Flow Firm Q/Q Growth
152.69% -3.35% 106.83% -100.11% -87,442.62% 13.87% -176.80% 45.98% - -1,818.34% 348.40%
Invested Capital Q/Q Growth
-3.49% -1.14% -1.92% 8.15% 3.36% -2.00% 8.65% 0.48% - 2.06% -2.32%
Profitability Metrics
- - - - - - - - - - -
EBITDA Margin
72.38% 79.73% 97.12% 86.18% 89.06% 82.19% 93.62% 91.46% - 89.20% 89.66%
EBIT Margin
28.03% 38.33% 58.24% 50.90% 52.16% 47.55% 58.12% 61.94% - 57.50% 73.48%
Profit (Net Income) Margin
31.60% 36.35% 58.90% 51.97% 53.17% 47.77% 61.18% 65.65% - 57.41% 72.09%
Tax Burden Percent
91.43% 96.54% 98.45% 103.20% 98.16% 97.79% 95.44% 96.66% - 99.16% 99.98%
Interest Burden Percent
123.32% 98.25% 102.72% 98.95% 103.84% 102.73% 110.30% 109.64% - 100.68% 98.14%
Effective Tax Rate
6.73% 3.59% 1.67% 2.98% 2.51% 3.15% 3.08% 2.34% - 3.19% 1.22%
Return on Invested Capital (ROIC)
2.08% 3.20% 5.01% 4.34% 4.59% 4.48% 5.40% 5.95% - 5.87% 9.44%
ROIC Less NNEP Spread (ROIC-NNEP)
2.27% 3.17% 5.07% 4.46% 4.69% 4.56% 5.63% 6.24% - 5.98% 9.38%
Return on Net Nonoperating Assets (RNNOA)
3.11% 4.43% 6.54% 5.48% 5.47% 5.01% 5.98% 6.38% - 5.12% 7.82%
Return on Equity (ROE)
5.19% 7.63% 11.55% 9.82% 10.05% 9.48% 11.38% 12.33% - 10.99% 17.25%
Cash Return on Invested Capital (CROIC)
5.48% 6.01% 9.95% 2.71% -3.64% -2.23% -12.43% -4.68% - 0.87% 13.87%
Operating Return on Assets (OROA)
2.16% 3.21% 4.93% 4.34% 4.55% 4.47% 5.38% 5.89% - 5.86% 9.23%
Return on Assets (ROA)
2.44% 3.04% 4.98% 4.43% 4.64% 4.49% 5.67% 6.24% - 5.85% 9.05%
Return on Common Equity (ROCE)
4.93% 7.24% 10.98% 9.37% 9.60% 9.07% 10.89% 11.82% - 10.51% 16.53%
Return on Equity Simple (ROE_SIMPLE)
0.00% 8.01% 9.08% 8.50% 0.00% 9.71% 9.70% 11.00% - 12.64% 16.61%
Net Operating Profit after Tax (NOPAT)
47 70 114 109 111 108 129 170 - 154 382
NOPAT Margin
26.14% 36.95% 57.27% 49.38% 50.85% 46.05% 56.33% 60.49% - 55.67% 72.58%
Net Nonoperating Expense Percent (NNEP)
-0.19% 0.02% -0.07% -0.11% -0.10% -0.09% -0.23% -0.29% - -0.11% 0.06%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue
53.57% 57.23% 48.89% 53.20% 48.17% 50.28% 43.96% 39.44% - 43.69% 27.47%
Earnings before Interest and Taxes (EBIT)
50 73 116 113 114 112 133 175 - 159 387
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
129 152 193 191 195 193 215 258 - 246 472
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.91 2.12 2.24 2.49 2.21 2.26 2.13 2.47 - 2.49 2.63
Price to Tangible Book Value (P/TBV)
2.33 2.60 2.71 2.95 2.58 2.62 2.44 2.84 - 2.85 2.99
Price to Revenue (P/Rev)
9.55 9.74 10.77 12.96 12.10 12.19 11.81 12.99 - 12.74 11.00
Price to Earnings (P/E)
28.16 27.26 25.38 30.16 24.70 23.96 22.53 23.12 - 20.49 16.54
Dividend Yield
9.63% 8.80% 7.96% 6.58% 7.21% 7.04% 7.31% 6.35% - 6.12% 5.62%
Earnings Yield
3.55% 3.67% 3.94% 3.32% 4.05% 4.17% 4.44% 4.33% - 4.88% 6.05%
Enterprise Value to Invested Capital (EV/IC)
1.32 1.41 1.53 1.64 1.52 1.60 1.48 1.65 - 1.78 1.89
Enterprise Value to Revenue (EV/Rev)
16.28 16.08 17.00 18.75 17.50 17.00 16.74 17.61 - 17.31 14.17
Enterprise Value to EBITDA (EV/EBITDA)
20.76 19.78 19.63 22.15 19.87 19.28 18.85 19.55 - 18.55 15.16
Enterprise Value to EBIT (EV/EBIT)
49.32 41.42 37.40 40.84 34.93 32.58 31.52 31.32 - 28.55 21.02
Enterprise Value to NOPAT (EV/NOPAT)
50.55 42.90 38.56 42.23 35.86 33.44 32.47 32.20 - 29.26 21.41
Enterprise Value to Operating Cash Flow (EV/OCF)
18.83 18.71 19.55 22.15 19.38 19.19 18.00 19.25 - 19.30 20.54
Enterprise Value to Free Cash Flow (EV/FCFF)
23.71 23.15 14.94 60.82 0.00 0.00 0.00 0.00 - 210.32 13.28
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.35 1.36 1.19 1.10 1.02 0.90 0.96 0.95 - 0.81 0.71
Long-Term Debt to Equity
1.34 1.35 1.18 1.10 1.02 0.90 0.96 0.95 - 0.74 0.71
Financial Leverage
1.37 1.40 1.29 1.23 1.17 1.10 1.06 1.02 - 0.86 0.83
Leverage Ratio
2.45 2.48 2.37 2.30 2.24 2.17 2.13 2.09 - 1.92 1.90
Compound Leverage Factor
3.02 2.43 2.43 2.28 2.32 2.23 2.35 2.29 - 1.93 1.86
Debt to Total Capital
57.39% 57.60% 54.44% 52.47% 50.56% 47.41% 49.07% 48.78% - 44.88% 41.63%
Short-Term Debt to Total Capital
0.23% 0.23% 0.82% 0.00% 0.00% 0.00% 0.00% 0.00% - 4.29% 0.06%
Long-Term Debt to Total Capital
57.16% 57.37% 53.62% 52.47% 50.56% 47.41% 49.07% 48.78% - 40.58% 41.57%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital
2.13% 2.14% 2.22% 2.08% 2.03% 2.04% 1.97% 2.03% - 2.66% 2.60%
Common Equity to Total Capital
40.48% 40.26% 43.35% 45.45% 47.41% 50.55% 48.96% 49.19% - 52.46% 55.76%
Debt to EBITDA
9.04 8.08 6.97 7.09 6.62 5.73 6.27 5.78 - 4.68 3.34
Net Debt to EBITDA
8.25 7.50 6.91 6.56 5.87 5.21 5.30 4.89 - 4.62 3.18
Long-Term Debt to EBITDA
9.01 8.05 6.87 7.09 6.62 5.73 6.27 5.78 - 4.23 3.33
Debt to NOPAT
22.03 17.52 13.69 13.51 11.95 9.93 10.80 9.53 - 7.38 4.71
Net Debt to NOPAT
20.09 16.26 13.58 12.51 10.59 9.03 9.13 8.05 - 7.29 4.49
Long-Term Debt to NOPAT
21.94 17.45 13.49 13.51 11.95 9.93 10.80 9.53 - 6.67 4.70
Noncontrolling Interest Sharing Ratio
5.04% 5.08% 4.90% 4.61% 4.50% 4.38% 4.30% 4.15% - 4.38% 4.18%
Liquidity Ratios
- - - - - - - - - - -
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
307 315 652 -0.72 -629 -542 -1,499 -810 - -364 905
Operating Cash Flow to CapEx
278.68% 706.27% 530.37% 727.58% 909.79% 516.12% 0.00% 1,067.64% - 1,680.72% 1,572.11%
Free Cash Flow to Firm to Interest Expense
5.17 5.45 12.08 -0.01 -11.38 -10.36 -28.34 -13.93 - -7.32 18.80
Operating Cash Flow to Interest Expense
2.78 2.62 3.41 3.38 4.15 3.48 4.52 3.90 - 4.33 4.52
Operating Cash Flow Less CapEx to Interest Expense
1.78 2.25 2.77 2.92 3.69 2.81 4.57 3.54 - 4.07 4.24
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.08 0.08 0.08 0.09 0.09 0.09 0.09 0.10 - 0.10 0.13
Fixed Asset Turnover
0.11 0.12 0.12 0.13 0.14 0.14 0.14 0.15 - 0.16 0.19
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
8,830 8,729 8,561 9,259 9,570 9,378 10,189 10,239 - 9,896 9,667
Invested Capital Turnover
0.08 0.09 0.09 0.09 0.09 0.10 0.10 0.10 - 0.11 0.13
Increase / (Decrease) in Invested Capital
-261 -245 -538 110 740 650 1,628 980 - 518 -523
Enterprise Value (EV)
11,630 12,311 13,126 15,184 14,521 14,966 15,035 16,882 - 17,603 18,291
Market Capitalization
6,820 7,459 8,315 10,494 10,037 10,732 10,606 12,455 - 12,952 14,199
Book Value per Share
$14.59 $14.22 $15.02 $16.32 $16.81 $16.82 $17.24 $17.07 - $17.56 $18.10
Tangible Book Value per Share
$11.96 $11.62 $12.41 $13.82 $14.42 $14.54 $15.01 $14.89 - $15.38 $15.94
Total Capital
8,830 8,729 8,561 9,259 9,570 9,378 10,189 10,239 - 9,896 9,667
Total Debt
5,067 5,028 4,661 4,858 4,839 4,446 5,000 4,995 - 4,441 4,025
Total Long-Term Debt
5,047 5,008 4,590 4,858 4,839 4,446 5,000 4,995 - 4,016 4,019
Net Debt
4,623 4,665 4,621 4,498 4,290 4,042 4,228 4,220 - 4,388 3,840
Capital Expenditures (CapEx)
59 21 35 25 25 35 -2.31 21 - 13 14
Net Nonoperating Expense (NNE)
-9.76 1.14 -3.24 -5.73 -5.08 -4.03 -11 -15 - -4.81 2.60
Net Nonoperating Obligations (NNO)
5,067 5,028 4,661 4,858 4,839 4,446 5,000 4,995 - 4,441 4,025
Total Depreciation and Amortization (D&A)
79 79 77 78 81 81 82 83 - 88 85
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.24 $0.27 $0.46 $0.43 $0.41 $0.34 $0.46 $0.60 $0.56 $0.47 $1.21
Adjusted Weighted Average Basic Shares Outstanding
245.30M 247.10M 257.84M 269.95M 281.84M 289.40M 295M 295.53M 295.57M 297.80M 303.01M
Adjusted Diluted Earnings per Share
$0.23 $0.27 $0.45 $0.42 $0.41 $0.33 $0.46 $0.59 $0.56 $0.47 $1.19
Adjusted Weighted Average Diluted Shares Outstanding
245.30M 247.10M 257.84M 269.95M 281.84M 289.40M 295M 295.53M 295.57M 297.80M 303.01M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
245.30M 247.10M 257.84M 269.95M 281.84M 289.40M 295M 295.53M 295.57M 297.80M 303.01M
Normalized Net Operating Profit after Tax (NOPAT)
45 79 111 124 114 111 123 172 - 160 403
Normalized NOPAT Margin
25.31% 41.64% 55.81% 55.99% 51.98% 47.17% 53.52% 61.09% - 58.10% 76.50%
Pre Tax Income Margin
34.56% 37.66% 59.82% 50.36% 54.17% 48.85% 64.11% 67.92% - 57.89% 72.11%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.84 1.26 2.15 2.06 2.07 2.13 2.52 3.00 - 3.19 8.04
NOPAT to Interest Expense
0.79 1.22 2.11 2.00 2.02 2.07 2.45 2.93 - 3.09 7.94
EBIT Less CapEx to Interest Expense
-0.15 0.89 1.50 1.59 1.61 1.46 2.57 2.64 - 2.93 7.75
NOPAT Less CapEx to Interest Expense
-0.21 0.85 1.47 1.53 1.56 1.39 2.49 2.57 - 2.83 7.66
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
269.40% 241.37% 204.28% 194.82% 171.06% 162.28% 160.59% 144.99% - 127.50% 94.44%
Augmented Payout Ratio
269.40% 241.37% 204.28% 194.82% 171.06% 162.28% 160.59% 144.99% - 127.50% 94.44%

Financials Breakdown Chart

Key Financial Trends

Omega Healthcare Investors (NYSE: OHI) showed a mixed start to 2026, with solid operating cash flow and earnings, but also a smaller cash balance and continued reliance on debt and equity financing.

Over the last several years, OHI has generally produced steady quarterly profitability and operating cash flow, supported by recurring rental and related income. However, the balance sheet still shows meaningful leverage, and results continue to be influenced by investment gains/losses, credit loss provisions, and financing activity. The latest quarter shows the company remains capable of covering operations and dividends at a basic level, but there are signs of pressure in liquidity and capital structure.

  • Operating cash flow remained strong in Q1 2026. OHI generated $215.5 million of net cash from operations, which compares favorably with recent quarters and supports its dividend-paying profile.
  • Net income stayed healthy. Q1 2026 consolidated net income came in at $158.6 million, with $151.0 million attributable to common shareholders.
  • Revenue growth remained intact year over year. Total revenue in Q1 2026 was $276.2 million, up from $234.6 million in Q1 2025 and ahead of most quarterly results over the past year.
  • EPS improved versus the prior year. Basic EPS was $0.47 in Q1 2026, up from $0.34 in Q1 2025 and $0.41 in Q4 2024.
  • Dividend coverage from operations appears manageable in the near term. Quarterly operating cash flow exceeded the $0.67 per-share dividend, though this does not fully remove long-term payout risk.
  • Depreciation remains large but is typical for the business model. Q1 2026 depreciation expense was $84.1 million, continuing to weigh on accounting earnings but not on cash generation as much as a non-cash charge.
  • OHI continues to carry substantial debt. Total debt was about $4.44 billion at March 31, 2026, including $425 million of short-term debt and $4.02 billion of long-term debt.
  • Equity remains positive, but retained earnings are still deeply negative. Total common equity was $5.19 billion, while retained earnings were $(3.67) billion, reflecting years of cumulative distributions and accounting charges.
  • Cash and equivalents dropped sharply from year-end. Cash and due from banks fell to $26.1 million in Q1 2026 from $737.2 million in Q3 2025, indicating much tighter liquidity.
  • Investing activity consumed significant cash. Q1 2026 net cash used in investing activities was $(270.0) million, driven by $333.5 million of investment purchases.

Three-year trend summary: OHI’s quarterly earnings and operating cash flow have held up relatively well, with net income generally ranging from the low-$100 million area to the high-$100 million area in recent periods. That said, the company’s financial profile has also shown repeated dependence on financing transactions, including debt issuance, equity issuance, and debt repayment. The balance sheet has expanded and contracted, but leverage remains material, and liquidity can swing significantly quarter to quarter.

What stands out for investors: OHI still looks like a business that can produce cash and profits, but the margin for error is not huge. If operating performance softens, the combination of large debt, dividend obligations, and investment activity could become more of a constraint. On the other hand, continued strong cash from operations would help support the dividend and reduce pressure on the balance sheet.

07/31/26 07:49 AM ETAI Generated. May Contain Errors.

Omega Healthcare Investors Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Omega Healthcare Investors' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Omega Healthcare Investors' net income appears to be on an upward trend, with a most recent value of $609.47 million in 2025, rising from $233.32 million in 2015. The previous period was $417.80 million in 2024. View Omega Healthcare Investors' forecast to see where analysts expect Omega Healthcare Investors to go next.

Over the last 10 years, Omega Healthcare Investors' total revenue changed from $743.62 million in 2015 to $975.06 million in 2025, a change of 31.1%.

Omega Healthcare Investors' total liabilities were at $4.61 billion at the end of 2025, a 10.8% decrease from 2024, and a 18.5% increase since 2015.

In the past 10 years, Omega Healthcare Investors' cash and equivalents has ranged from $5.42 million in 2015 to $518.34 million in 2024, and is currently $27.02 million as of their latest financial filing in 2025.



Financial statements for NYSE:OHI last updated on 7/30/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners